Literature DB >> 11040119

Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5.

Y Feng1, M Leavitt, R Tritz, E Duarte, D Kang, M Mamounas, P Gilles, F Wong-Staal, S Kennedy, J Merson, M Yu, J R Barber.   

Abstract

CCR-5 is a major cellular coreceptor for R5 strains of HIV-1. Individuals carrying a homozygous 32-base-pair deletion in this gene are apparently healthy and are relatively resistant to HIV-1 infection. Since CCR5 appears to be dispensable for the host, but important for initial HIV-1 infection, CCR5 mRNA is an excellent therapeutic target for inhibiting HIV-1 replication via ribozyme knockout. We report here that hairpin ribozymes are able to reduce cellular CCR5 mRNA and cell surface CCR5 when stably introduced into PM1 cells by transduction with recombinant adenoassociated viral vector. The ribozymes effectively protect the cells from infection by R5 HIV-1 strains or non-syncytium-inducing clinical isolates commensurate with a reduction in CCR5 mRNA. These results suggest a novel gene therapy approach to preventing or slowing the disease progression of HIV-1 infection. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040119     DOI: 10.1006/viro.2000.0536

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

1.  Anti-HBV hairpin ribozyme-mediated cleavage of target RNA in vitro.

Authors:  Yu-Hu Song; Ju-Sheng Lin; Nan-Zhi Liu; Xin-Juan Kong; Na Xie; Nan-Xia Wang; You-Xin Jin; Kuo-Huan Liang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

Review 2.  Hematopoietic-stem-cell-based gene therapy for HIV disease.

Authors:  Hans-Peter Kiem; Keith R Jerome; Steven G Deeks; Joseph M McCune
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

Review 3.  HIV/AIDS eradication.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Bioorg Med Chem Lett       Date:  2013-05-18       Impact factor: 2.823

Review 4.  Cell-based gene therapy against HIV.

Authors:  R Dey; B Pillai
Journal:  Gene Ther       Date:  2015-06-16       Impact factor: 5.250

5.  Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site.

Authors:  Scott R Eberhardy; Joao Goncalves; Sofia Coelho; David J Segal; Ben Berkhout; Carlos F Barbas
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

6.  Glycosyl-Phosphatidylinositol-Anchored Anti-HIV Env Single-Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity.

Authors:  Anisha Misra; Emile Gleeson; Weiming Wang; Chaobaihui Ye; Paul Zhou; Jason T Kimata
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

Review 7.  Stem cell-based anti-HIV gene therapy.

Authors:  Scott G Kitchen; Saki Shimizu; Dong Sung An
Journal:  Virology       Date:  2011-01-17       Impact factor: 3.616

Review 8.  Creating genetic resistance to HIV.

Authors:  John C Burnett; John A Zaia; John J Rossi
Journal:  Curr Opin Immunol       Date:  2012-09-15       Impact factor: 7.486

9.  Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides.

Authors:  Marc Egelhofer; Gunda Brandenburg; Holger Martinius; Patricia Schult-Dietrich; Gregory Melikyan; Renate Kunert; Christopher Baum; Ingrid Choi; Alexander Alexandrov; Dorothee von Laer
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach.

Authors:  Shani Waninger; Kelli Kuhen; Xiuyuan Hu; Jon E Chatterton; Flossie Wong-Staal; Hengli Tang
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.